Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2017

Summary

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies.  The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.   The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 4 and 7 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Dermatology, Musculoskeletal Disorders, Cardiovascular and Oncology which include indications Multiple Sclerosis, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis, Cardiovascular Disease, Colitis, Crohn's Disease (Regional Enteritis), Dermatological Disorders, Dermatomyositis, Graft Versus Host Disease (GVHD), Inflammation, Inflammatory Bowel Disease, Kidney Transplant Rejection, Primary Biliary Cirrhosis, Relapsing Multiple Sclerosis (RMS) and Systemic Lupus Erythematosus. 

Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
- The report reviews Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
-  The report reviews latest news and deals related to Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sphingosine 1 Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents
 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview 7
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 12
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development 20
Actelion Ltd 20
Arena Pharmaceuticals Inc 20
Astellas Pharma Inc 21
AstraZeneca Plc 21
Bristol-Myers Squibb Company 22
Celgene Corp 23
GlaxoSmithKline Plc 23
Idorsia Ltd 24
LG Chem, Ltd. 24
Novartis AG 25
Sanofi 25
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles 26
AKP-11 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ASP-0028 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
BMS-986104 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CBP-307 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
cenerimod - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
CP-9531 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
etrasimod arginine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
FP-253 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
LC-510255 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
NIBR-0213 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ozanimod hydrochloride - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ponesimod - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
SAR-247799 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
siponimod - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products 59
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products 61
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones 62
Featured News & Press Releases 62
May 22, 2017: Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis 62
Feb 21, 2017: TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis 62
Feb 17, 2017: Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis 63
Feb 09, 2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017 64
Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG 64
Oct 13, 2016: Celgene to Present New Data on Ozanimod at UEGW and ACG Congresses 66
Oct 11, 2016: Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting 67
Sep 29, 2016: Actelion To Investigate All-Oral Combination Therapy For Patients With Relapsing Multiple Sclerosis 67
Sep 17, 2016: Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients 68
Sep 16, 2016: Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS 69
Aug 25, 2016: Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS 70
Jun 13, 2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334 70
May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis 70
Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial 71
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by Actelion Ltd, H2 2017 20
Pipeline by Arena Pharmaceuticals Inc, H2 2017 20
Pipeline by Astellas Pharma Inc, H2 2017 21
Pipeline by AstraZeneca Plc, H2 2017 21
Pipeline by Bristol-Myers Squibb Company, H2 2017 22
Pipeline by Celgene Corp, H2 2017 23
Pipeline by GlaxoSmithKline Plc, H2 2017 23
Pipeline by Idorsia Ltd, H2 2017 24
Pipeline by LG Chem, Ltd., H2 2017 24
Pipeline by Novartis AG, H2 2017 25
Pipeline by Sanofi, H2 2017 25
Dormant Products, H2 2017 59
Dormant Products, H2 2017 (Contd..1), H2 2017 60
Discontinued Products, H2 2017 61